Home
Conferences
Events
Media
Publications
Resources
NCCN
ASCO
Hematology
Sign In
Home
Conferences
Events
Media
Publications
Resources
Search
Home
Conferences
Events
Media
Publications
Resources
NCCN
ASCO
Hematology
Trending →
T-DXd Plus Pertuzumab Receives FDA Approval, Shifting the Frontline HER2-Positive Paradigm
By
MedOnc2
December 15, 2025
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA2-Mutated mCSPC
By
MedOnc2
December 15, 2025
FDA Approves Durvalumab for Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
By
MedOnc2
December 15, 2025
FDA Grants Traditional Approval to Pirtobrutinib (Jaypirca®) for CLL/SLL
By
MedOnc2
December 15, 2025
Enfortumab Vedotin + Pembrolizumab for Muscle-Invasive Bladder Cancer (MIBC)
By
MedOnc2
November 22, 2025
Login
Sign In
Follow US
Medonc
Follow:
25
Articles
ADRIATIC TRIAL SCLC: maintenance Durvalumab shows 2 year improvement in OS
August 26, 2025
Myeloma induction: can AI generate a treatment algorithm ?
August 21, 2025
Uncategorized
AQUILA study shows PFS and OS benefit in smoldering myeloma
September 14, 2025
NRG oncology BN007- no PFS benefit with dual immunotherapy and radiation in MGMT unmethylated GBM
August 21, 2025
Keynote-689, perioperative pembrolizumab shows efficacy in resectable head and neck cancer patients with tumors expressing PDL1
August 13, 2025
Head and Neck: NIVOPOSTOP study shows efficacy in adjuvant setting
August 13, 2025
AUGMENT-101 phase I/II study for patients with KMT2Ar or NPM1 mutation in R/R AML
August 13, 2025
STRIDE in HCC: 5 year follow up data
August 11, 2025
Checkmate-9DW: Dual immunotherapy in front line HCC
August 11, 2025
LEAP-015: Addition of Lenvatinib and Pembrolizumab to chemotherapy shows modest improvement in PFS in advanced Esophageal and GEJ cancers
August 11, 2025
Phase III RINDBeRG trial, no impact of continuing Ramucirumab beyond 2nd line in Gastric and GEJ adenocarcinoma
August 11, 2025
Perioperative chemoimmunotherapy bladder cancer, phase III NIAGARA TRIAL
August 11, 2025
Show More
